title: Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma.
abstract: OBJECTIVE
  To retrospectively evaluate the effectiveness, tolerance, and predictors of response to transcatheter arterial chemoembolization for treatment of liver metastases from adrenocortical carcinoma.
  
  
  METHODS
  Twenty-nine patients with progressive liver metastases from adrenocortical carcinoma were treated with transcatheter arterial chemoembolization. Rate and duration of tumor response were defined according to Response Evaluation Criteria In Solid Tumors. The size of liver metastases, percentage of liver involvement, and Lipiodol uptake were studied as potential predictive factors of response. Time to liver and metastatic lesion progression were considered as endpoints.
  
  
  RESULTS
  Three months after transcatheter arterial chemoembolization, a liver morphologic response was observed in six of 29 patients (21%), stabilization in 18 (62%), and progression in five (17%). According to per-lesion analysis (n = 103), a morphologic response was observed in 23 lesions (22%), stabilization in 67 (65%), and progression in 13 (13%). Higher response rates were observed in cases in which the diameter of the target metastasis was 3 cm or smaller (P = .002) and in cases of high Lipiodol uptake (> 50%; P < .0001). On per-patient and per-lesion bases, progression rates were 32% and 55% at 6 months and 23% and 38% at 12 months. The median time to progression was 9 months and median survival was 11 months after the first procedure.
  
  
  CONCLUSIONS
  Transcatheter arterial chemoembolization should be considered as part of the therapeutic arsenal to treat liver metastases from adrenocortical carcinoma. The size of liver metastases and the percentage of Lipiodol uptake may help identify patients likely to benefit most from transcatheter arterial chemoembolization.
authors.affiliation: Department of Interventional Radiology, Institut Gustave Roussy, 39 Rue Camille Desmoulins, Villejuif 94805, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Cazejust
authors.forename: Thierry
authors.initials: T
authors.lastname: De Baère
authors.forename: Anne
authors.initials: A
authors.lastname: Auperin
authors.forename: Frédéric
authors.initials: F
authors.lastname: Deschamps
authors.forename: Lukas
authors.initials: L
authors.lastname: Hechelhammer
authors.forename: Mohamed
authors.initials: M
authors.lastname: Abdel-Rehim
authors.forename: Martin
authors.initials: M
authors.lastname: Schlumberger
authors.forename: Sophie
authors.initials: S
authors.lastname: Leboulleux
authors.forename: Eric
authors.initials: E
authors.lastname: Baudin
mesh_terms: D000293:Adolescent; D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy*; D018268:Adrenocortical Carcinoma / Q000188:drug therapy* / Q000556:secondary*; D000328:Adult; D000368:Aged; D002406:Catheterization, Peripheral; D016461:Chemoembolization, Therapeutic; D005260:Female; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D006490:Hemostatics